Repligen (NASDAQ:RGEN) Price Target Raised to $175.00 at Evercore ISI

Key Points

• Evercore ISI has raised its price target for Repligen from $155.00 to $175.00, suggesting a potential upside of 20.98% based on the stock's last closing price.
• The company reported a 14.8% increase in quarterly revenue compared to the same quarter last year, reaching $182.37 million, even though earnings per share of $0.37 fell short of analysts' expectations.
• Repligen currently holds a consensus rating of "Moderate Buy", with one analyst rating it as a Strong Buy and a total of ten assigning Buy ratings.

Repligen (NASDAQ:RGEN - Get Free Report) had its price objective hoisted by analysts at Evercore ISI from $155.00 to $175.00 in a report issued on Tuesday,Benzinga reports. The firm currently has an "outperform" rating on the biotechnology company's stock. Evercore ISI's target price would suggest a potential upside of 20.98% from the stock's previous close.

Several other equities analysts have also recently commented on the stock. Stephens upgraded shares of Repligen to an "overweight" rating and set a $160.00 target price for the company in a research note on Tuesday, July 22nd. Barclays upped their target price on shares of Repligen from $150.00 to $160.00 and gave the company an "overweight" rating in a research note on Thursday, October 2nd. HC Wainwright reiterated a "buy" rating and set a $180.00 target price on shares of Repligen in a research note on Wednesday, September 3rd. Royal Bank Of Canada reiterated an "outperform" rating and set a $205.00 target price on shares of Repligen in a research note on Tuesday, September 2nd. Finally, Wells Fargo & Company cut their target price on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research note on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $169.62.

Repligen Stock Performance

Shares of Repligen stock traded down $5.44 on Tuesday, reaching $144.66. The stock had a trading volume of 685,831 shares, compared to its average volume of 790,203. The business's 50-day moving average price is $122.99 and its two-hundred day moving average price is $125.35. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. Repligen has a fifty-two week low of $102.96 and a fifty-two week high of $182.52. The stock has a market cap of $8.14 billion, a P/E ratio of -578.78, a price-to-earnings-growth ratio of 2.74 and a beta of 1.08.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The firm had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. During the same quarter in the previous year, the firm posted $0.40 earnings per share. Repligen's quarterly revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, sell-side analysts forecast that Repligen will post 1.72 EPS for the current year.

Insider Buying and Selling at Repligen

In other news, Director Martin D. Madaus bought 1,800 shares of the stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $112.13 per share, with a total value of $201,834.00. Following the acquisition, the director owned 1,800 shares in the company, valued at $201,834. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.20% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. acquired a new stake in shares of Repligen in the 3rd quarter valued at approximately $5,423,000. Moody National Bank Trust Division acquired a new stake in shares of Repligen in the 3rd quarter valued at approximately $212,000. Texas Permanent School Fund Corp raised its position in shares of Repligen by 36.2% in the 2nd quarter. Texas Permanent School Fund Corp now owns 25,141 shares of the biotechnology company's stock valued at $3,127,000 after acquiring an additional 6,688 shares during the period. Squarepoint Ops LLC raised its position in shares of Repligen by 49.7% in the 2nd quarter. Squarepoint Ops LLC now owns 73,792 shares of the biotechnology company's stock valued at $9,178,000 after acquiring an additional 24,510 shares during the period. Finally, Headlands Technologies LLC acquired a new stake in shares of Repligen in the 2nd quarter valued at approximately $353,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.